my.newpaltz.edu | Blackboard | Hawkmail | Library | Zimbra

A-Z Index | Contact Us | People-Finder

» Current Students | » Faculty & Staff | » Future Students | » Parents | » Alumni, Donors & Friends | » Athletics | » Employment | » Give Today!

photo of people marching on campus

Events

Bookmark and Share

Dr. George Yancopoulos, "The Next Generation of Cancer Targets"

Date: 05/01/08
Time: 4 - 5 p.m.
Audience: Public
Sponsored By: School of Science and Engineering
Location: Coykendall Science Building Auditorium
Contact: David Clark, x3524, clarkd@newpaltz.edu

Much research is focused on basic mechanisms that lead to the development of cancer. The production of new blood vessels (angiogenesis) is necessary for solid tumors to grow, and thus an understanding of this process can lead to the development of anti-cancer therapies that block angiogenesis. Regeneron is pioneering work that exploits new technologies to accelerate the discovery of proteins which play a role in angiogenesis. With these technologies, a previously unknown protein, D114, was identified as an angiogenesis factor. Regeneron is now developing anti-angiogenesis therapies that will block the action of D114 and thus block the growth of tumors. Dr. Yancopoulos, President of Regeneron Research Laboratories, will present his group's recent advances in this work.